C. J. Hawkey

发表

Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib – study design and patient demographics

M. Farkouh, P. Richardson, C. J. Hawkey, 2004, Alimentary pharmacology & therapeutics.

Non‐steroidal anti‐inflammatory drug associated ulcer: Epidemiology, causation and treatment

P. Brooks, F. Silverstein, M. Langman, 1991, Journal of gastroenterology and hepatology.

Low‐dose misoprostol for the prevention of low‐dose aspirin‐induced gastroduodenal injury

A. Goddard, S. Morant, M. Shield, 2000, Alimentary pharmacology & therapeutics.

Ranitidine bismuth citrate and aspirin‐induced gastric mucosal injury

F. Murray, A. Cole, C. J. Hawkey, 1993, Alimentary pharmacology & therapeutics.

Prophylaxis of aspirin‐induced gastric mucosal bleeding with ranitidine

C. Hawkey, K. Somerville, C. J. Hawkey, 1988, Alimentary pharmacology & therapeutics.

Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials

I. Wiklund, C. Hawkey, E. Mayer, 2001, Alimentary pharmacology & therapeutics.

Review article: aspirin and gastrointestinal bleeding

C. J. Hawkey, C. J. Hawkey, 1994, Alimentary pharmacology & therapeutics.

Low dose aspirin: selective inhibition of rectal dialysis thromboxane B2 in healthy volunteers

P. Hyman-Taylor, A. Cole, C. J. Hawkey, 1994, Alimentary pharmacology & therapeutics.

Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti‐inflammatory drugs early after the initiation of treatment – findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial

D. Richard, G. Krammer, R. Rebuli, 2008, Alimentary pharmacology & therapeutics.

Review: acute human models of gastric mucosal injury

C. J. Hawkey, C. Hawkey, 1987, Alimentary pharmacology & therapeutics.

Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin

C. Hawkey, Á. Lanas, N. Talley, 2005, Alimentary pharmacology & therapeutics.

Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding

J. Atherton, C. Hawkey, W. Stack, 2002, Alimentary pharmacology & therapeutics.

Commentary: risk factors for gastrointestinal bleeding in NSAID users

C. J. Hawkey, 2012, Alimentary pharmacology & therapeutics.

Clinical trial: healing of NSAID‐associated gastric ulcers in patients continuing NSAID therapy – a randomized study comparing ranitidine with esomeprazole

J. Johanson, J. Goldstein, C. J. Hawkey, 2007, Alimentary pharmacology & therapeutics.

Helicobacter pylori, NSAIDs and cognitive dissonance

C. Hawkey, C. J. Hawkey, 1999, Alimentary pharmacology & therapeutics.

Review article: COX‐II inhibitors—a new generation of safer NSAIDs?

C. Hawkey, C. J. Hawkey, M. Donnelly, 1997, Alimentary pharmacology & therapeutics.

Enhanced eradication of Helicobacter pylori by pre‐ versus post‐prandial amoxycillin suspension with omeprazole: implications for antibiotic delivery

R. Spiller, J. Atherton, D. Cullen, 1996, Alimentary pharmacology & therapeutics.

Gastric microbleeding following single and repeated dosing with naproxen

N. Yeomans, C. J. Hawkey, G. Cook, 1995, Alimentary pharmacology & therapeutics.

Nature and time‐course of piroxicam‐induced injury to human gastric mucosa

C. Hawkey, I. Fellows, C. J. Hawkey, 1989, Alimentary pharmacology & therapeutics.

The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase‐2, in humans

L. Jackson, T. Simon, E. Mortensen, 2001, Alimentary pharmacology & therapeutics.

Non‐steroidal anti‐inflammatory drugs and the gastric mucosa: mechanisms of damage and protection

C. Hawkey, C. J. Hawkey, C. Hawkey, 1988, Alimentary pharmacology & therapeutics.

Predictors of gastroduodenal erosions in patients taking low‐dose aspirin

C. Hawkey, Á. Lanas, N. Talley, 2010, Alimentary pharmacology & therapeutics.

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials

C. Hawkey, L. Laine, J. Bolognese, 2001, Alimentary pharmacology & therapeutics.

Lansoprazole versus ranitidine for the treatment of reflux oesophagitis

I. Moules, C. Hawkey, K. Wormsley, 1995, Alimentary pharmacology & therapeutics.

Prescribing of nonsteroidal anti‐inflammatory drugs in general practice: determinants and consequences

D. Greenwood, R. Logan, C. Hawkey, 1997, Alimentary pharmacology & therapeutics.

The place of cisapride in therapeutics: an interim verdict

C. Hawkey, C. J. Hawkey, 1991, Alimentary pharmacology & therapeutics.

Acetic acid‐enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrett's oesophagus

C. Hawkey, M. James, K. Ragunath, 2006, Alimentary pharmacology & therapeutics.

Novel endoscopic observation in Barrett’s oesophagus using high resolution magnification endoscopy and narrow band imaging

K. Yao, K. Ragunath, P. Kaye, 2007, Alimentary pharmacology & therapeutics.

Scintigraphic assessment of the intragastric distribution and gastric emptying of an encapsulated drug: the effect of feeding and of a proton pump inhibitor

R. Spiller, J. Atherton, C. Hawkey, 1994, Alimentary pharmacology & therapeutics.

A randomized, double‐blind, placebo‐controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease

A. Forbes, J. Mansfield, J. Zeldis, 2007, Alimentary pharmacology & therapeutics.

Safety and efficacy of 7‐day rabeprazole‐ and omeprazole‐based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease

J. Atherton, B. Thjódleifsson, C. Hawkey, 2003, Alimentary pharmacology & therapeutics.

Clinical trial: a randomized trial of early endoscopy, Helicobacter pylori testing and empirical therapy for the management of dyspepsia in primary care

A. Duggan, P. Miller, C. J. Hawkey, 2009, Alimentary pharmacology & therapeutics.

Non‐steroidal anti‐inflammatory drugs: who should receive prophylaxis?

C. Hawkey, C. J. Hawkey, 2004, Alimentary pharmacology & therapeutics.

Does concurrent prescription of selective serotonin reuptake inhibitors and non‐steroidal anti‐inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?

R. Hubbard, L. Smeeth, C. Hawkey, 2005, Alimentary pharmacology & therapeutics.

Twenty‐four‐hour intragastric acidity and clinical trial of bedtime enprostil 70 μg compared with ranitidine 300 mg in duodenal ulcer

R. Pounder, R. Logan, R. Walt, 1987 .

Abolition by omeprazole of aspirin induced gastric mucosal injury in man.

C. Hawkey, T. Daneshmend, C. J. Hawkey, 1990, Gut.

European Evidence Based Consensus on the Diagnosis and Management of Crohn's Disease: Special Situations 8.0 Risk Factors, Prophylaxis, Diagnosis, and Management of Postoperative Recurrence of Crohn's Disease (cd)

M. Gassull, M. Hamilton, C. J. Hawkey, 2022 .

Effect of allopurinol, sulphasalazine, and vitamin C on aspirin induced gastroduodenal injury in human volunteers.

M. McAlindon, C. Hawkey, A. Muller, 1996, Gut.

Effect of reactive pharmacy intervention on quality of hospital prescribing.

C. Hawkey, S. Hodgson, T. Daneshmend, 1990, BMJ.

Ileo‐caecal ulceration associated with the use of diclofenac slow release

A. Swannell, C. J. Hawkey, R. Steele, 1993, Alimentary pharmacology & therapeutics.